English to Polish Medical Medical: Pharmaceuticals general

Dokumentacja badań klinicznych.

If subjects have previously received biologic therapy for UC (i.e., tumor necrosis factor [TNF] antagonists, vedolizumab or ustekinumab), they must have a washout period of 8 weeks prior to randomization, and any previous failure of biologic treatment is limited to only 1 class of biologic.
(Note: this inclusion criterion is only applicable until 58 subjects with prior exposure to biologic therapy have been randomized).